Login to Your Account

First biopharma IPO of Q3

Akcea Therapeutics prices low and boosts shares to complete $125M IPO

By Marie Powers
News Editor

Monday, July 17, 2017

Two years after its formation by Ionis Pharmaceuticals Inc., Akcea Therapeutics Inc. planted its own flag on the public markets, opening Friday as AKCA on Nasdaq. The Cambridge, Mass.-based company raised $125 million in its IPO by offering 15.625 million common shares – up from its expected offering of 9.62 million shares – at $8, below its intended range of $12 to $14.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription